Epstein Barr Virus Positive Diffuse Large B Cell Lymphoma Of The Elderly C2700007
An aggressive B-cell lymphoma associated with Epstein-Barr virus infection in older adults. It primarily affects people over 90 years old. Treatment depends on overall health, often involving immunotherapy and chemotherapy.
Key facts at a glance
- ICD-10
- C80.1
- ICD-11
- 2A00.0
- Body system
- oncologic
- Severity
- severe
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Generalized symptoms
(oncologic)Significant symptoms that substantially affect daily functioning.
Frequency: Common at all stages
Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Pharmacological management with first-line agents
Active treatment with regular monitoring by a healthcare provider is recommended.
R-CHOP Immunochemotherapy
Combination therapy using rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone to target cancer cells expressing CD20 surface antigen. This is the standard first-line approach for diffuse large B-cell lymphoma, typically administered in cycles over several months.
Additional treatment options
Involved-Field Radiation Therapy
Targeted radiation to sites of bulky disease or residual masses following chemotherapy. Particularly useful for localized disease presentation or palliation of symptomatic lesions.
procedureSupportive Care and Infection Prophylaxis
Comprehensive supportive management including antimicrobial prophylaxis, growth factor support for neutropenia, transfusion support as needed, and management of treatment-related side effects such as nausea and fatigue.
medicationNutritional Support
Dietetic assessment and support to maintain nutritional status during intensive treatment. Includes protein supplementation and management of treatment-related appetite changes and weight loss.
complementaryResponse Assessment and Surveillance
Regular imaging studies and interim assessments during treatment to evaluate response. PET-CT scanning at defined intervals to guide treatment decisions and identify disease progression or relapse.
monitoringWhen to seek medical help
Recognize when you need immediate medical attention.
See a doctor within 24 hours
Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.
Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.
Frequently asked questions
Common questions about this topic.
What is Epstein Barr Virus Positive Diffuse Large B Cell Lymphoma Of The Elderly C2700007?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalMedication Comparisons
Compare medications used to treat Epstein Barr Virus Positive Diffuse Large B Cell Lymphoma Of The Elderly C2700007. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy